Abstract Insulin resistance affects the vascular endothelium, and contributes to systemic insulin resistance by directly impairing the actions of insulin to redistribute blood flow as part of its normal actions driving muscle glucose uptake. Impaired vascular function is a component of the insulin resistance syndrome, and is a feature of type 2 diabetes. On this basis, the vascular endothelium has emerged as a therapeutic target where the intent is to improve systemic metabolic state by improving vascular function. We review the available literature presenting studies in humans, evaluating the effects of metabolically targeted and vascular targeted therapies on insulin action and systemic metabolism. Therapies that improve systemic insulin resistance exert strong concurrent effects to improve vascular function and vascular insulin action. RAS-acting agents and statins have widely recognized beneficial effects on vascular function but have not uniformly produced the hoped-for metabolic benefits. These observations support the notion that systemic metabolic benefits can arise from therapies targeted at the endothelium, but improving vascular insulin action does not result from all treatments that improve endothelium-dependent vasodilation. A better understanding of the mechanisms of insulin's actions in the vascular wall will advance our understanding of the specificity of these responses, and allow us to better target the vasculature for metabolic benefits.
Introduction
The vascular endothelium serves as the interface between the blood and the enclosing vascular structures. This unicellular layer serves a number of crucial roles in physiology and pathophysiology, including regulating vascular tone and promoting a local anti-inflammatory and anti-fibrotic milieu. The endothelium also contributes to the regulation of systemic metabolism by virtue of actions of fuel substrates, insulin, and other regulatory factors directly at the level of the vascular endothelium. In the present review we will summarize the effects of insulin resistance and diabetes mellitus on the endothelium, and mechanisms integrating vascular function and metabolism. This will provide context and rationale for a review of efforts targeting the endothelium for metabolic benefits in obesity, insulin resistance, and type 2 diabetes.
Role of the vasculature in normal metabolic physiology
The vasoregulatory function of the vascular endothelium is now recognized to contribute importantly to the net, integrated action of insulin in skeletal muscle [1] [2] [3] [4] [5] . Similar to the effect of acetylcholine to induce a receptor-mediated activation of production of nitric oxide by the endothelium, insulin acts through traditional insulin receptors on the vascular endothelium to stimulate production of nitric oxide and induce vasodilation [6] [7] [8] [9] . The endothelial insulin response is parallel to that in traditional insulin-responsive tissues, acting through a PI3 kinase pathway to activate the serine protease Akt/Protein Kinase B, which in turn activates endothelial nitric oxide synthase (eNOS, also known as NOS3).
This set of functions mediates insulin-mediated vasodilation in skeletal muscle and contribute to normal metabolic regulation of fuel disposal [2, 5, 10, 11] . Skeletal muscle is not fully perfused at rest, with an incompletely understood mechanism regulating tissue perfusion and providing temporary and shifting perfusion to sub-segments of the whole muscle. This reserve capacity for perfusion to the muscle allows the marked increase in perfusion that is required to support increased metabolic activity when the muscle is activated. This same system, via endothelial insulin receptor activation, supports increased perfusion of skeletal muscle in the postprandial state as part of the process of insulinstimulated postprandial glucose storage into muscle [12] [13] [14] . The experiments that first demonstrated this effect in humans used limb-balance studies, evaluating insulinmediated vasodilation at rest under insulin stimulation with and without the competitive NOS antagonist L-N monomethylarginine (L-NMMA) [15, 16] . L-NMMA blocked insulin-stimulated increases in limb blood flow and reduced insulin-stimulated limb glucose disposal. These and subsequent studies suggest that insulin's vascular actions contribute~10-40 % of the net action of insulin to stimulate glucose uptake in skeletal muscle under resting conditions [15] [16] [17] . Subsequent experiments using other methods, in particular studies using microbubble ultrasound to more specifically quantify microvascular perfusion, have confirmed the effect and localized the vascular action of insulin to microvessels [4, [12] [13] [14] 18] .
Insulin was only the first metabolically important hormone to be shown to induce endothelium-dependent vasodilation. Others with more recently established actions in animal models and in humans include leptin [19, 20] , adiponectin [21, 22] , and glucagon-like peptide-1 (GLP-1) [23] [24] [25] . Similar to insulin, the concentrations and dynamics of these factors are significantly altered under conditions of obesity and type 2 diabetes. The importance of these more recently studied factors to routine vascular health, and their contributions to the normal physiologic functions of metabolically active tissues, remains to be demonstrated.
Vascular dysfunction in insulin resistance/diabetes
Diabetes mellitus and insulin resistance without overt diabetes are associated with endothelial dysfunction [5, 11] . Studies exploring potential mechanisms for these effects have tested individual diabetes-associated factors as potential contributors to vascular dysfunction. In general these studies test whether the factor in question can induce vascular dysfunction in the non-diabetic state, then by subtraction or reduction of the factor in question whether that factor is an important contributor to dysfunction in diabetes. These studies have provided targets for interventions aimed at improving vascular function in insulin resistance and diabetes.
Therapies that target the endothelium
The endothelium has emerged as a therapeutic target in diabetes. This can be conceived as targeting improvements in diabetes-associated vascular risk, or targeting metabolic improvements by augmenting vascular insulin action through generic improvements in endothelial function or more directly improving vascular insulin action. Although these are conceptually distinct targets, clearly a therapy that improves endothelial function has the potential to simultaneously benefit both vascular and metabolic disease. For the purposes of the current review, we will focus on the assessment of metabolic effects of vascular therapies. The principal underlying hypothesis for these therapies is that, given the dependence of tissue insulin sensitivity on insulin action in the endothelium, whole-body insulin sensitivity and specifically vascular insulin sensitivity can be improved by therapies that reduce obesity/diabetes-associated metabolic abnormalities, improve tissue insulin sensitivity, or directly improve endothelial function.
The conceptual approaches can be divided into those targeting metabolic abnormalities, and those targeting the vasculature directly.
Metabolic therapies: glucose lowering
In cross-sectional studies, hyperglycemia is clearly associated with impaired vascular function and specifically with impaired endothelium-dependent vasodilation [26, 27] . A direct detrimental role of hyperglycemia on to the vasculature has been demonstrated most clearly by findings of acute impairment with experimentally induced hyperglycemia [28, 29] . Demonstrating improvement in vascular function with reductions in glucose is more difficult, because of confounding effects of most glucose-lowering therapies independent of benefits via glucose lowering. For example, glucose reductions with insulin therapy have been shown to improve endothelial function, but these benefits cannot be cleanly attributed to the glucose lowering effect alone [30, 31] . Even therapies that modulate glucose concentrations independent of direct effects on beta cell function or insulin sensitivity in peripheral tissues can produce secondary improvements in these parameters, as will be discussed below. With these limitations in mind, we can evaluate the effects of direct glucose-lowering therapies on vascular function.
The alpha-glucosidase inhibitors delay digestion and absorption of ingested carbohydrates. These therapies produce reductions in glucose excursions without direct effects on beta cell function or insulin sensitivity. Also these agents are not systemically absorbed and therefore confounding by direct effects on the vasculature is minimal. In clinical studies acarbose failed to improve agonist-induced endotheliumdependent vasodilation in subjects with type 2 DM [32], and miglitol has been shown to improve reactive hyperemiavasodilation where voglibose did not [33] . Miglitol also showed immediate improvement in the prandial effect to augment vasodilation [34] , through mechanisms that may involve acute effects on glucose excursion or secondary effects on meal-related hormones. Effects of agents in this class to improve whole-body insulin sensitivity have been reported [33, 35, 36] , but no studies have used these agents to evaluate effects of glucose lowering on vascular insulin sensitivity.
Another class that may be informative regarding direct effects of glucose lowering on vascular function is the glucosuric SGLT-2 inhibitors. These agents are systemically absorbed following ingestion, and act at the kidney to lower the threshold for urinary loss of glucose [37] . This class of agents is early in development, and neither preclinical studies nor clinical studies addressing effects on vascular function have been published to date.
With this limited dataset, we can conclude that there is modest but not convincing data that therapies directed at glucose lowering without concurrent effects in other metabolic parameters may improve endothelial function.
Metabolic therapies: insulin sensitizers
Experimental evidence has shown that insulin resistance at the level of the endothelium contributes to vascular dysfunction. In whole-animal or human experiments with insulin sensitizing therapies there are effects on systemic metabolism beyond the direct effects on insulin action, and net benefits at the level of the endothelium may reflect all of these concurrent effects. Nevertheless studies have been undertaken using insulin sensitizing therapies to target improvements in vascular function.
Metformin, a biguanide, acts predominantly at the liver to improve hepatic insulin sensitivity, and through resulting improvements in systemic metabolism as well as direct extrahepatic actions has concurrent effects on insulin sensitivity in other tissues [38, 39] . In clinical studies metformin has shown beneficial effects on endothelial function in insulin resistant subjects with Type 2 diabetes, and in other groups with insulin resistance [40] [41] [42] [43] . In some studies, metformin did not produce a significant benefit when compared against concurrently studied thiazolidinediones [44, 45], and it is not always the case that the improvement in vascular function is proportional to improved measures of insulin resistance. Nevertheless, the principal effect of metformin is on insulin resistance, and metformin therapy appears to improve vascular function.
The thiazolidinedione (TZD) class of antidiabetic agents has proven problematic in clinical applications, and at present the use of these agents is waning. Nevertheless these agents are extremely informative regarding questions of the interrelationships of insulin resistance, fatty acid disposition, and vascular health. Through effects on cellular fatty acid handling, principally in adipose tissue, TZDs improve peripheral and hepatic insulin sensitivity [46] . These agents produce concurrent improvements in insulin sensitivity and vascular function in Type 2 diabetes and related states of insulin resistance [44, 45, [47] [48] [49] [50] [51] [52] [53] . The exact mechanism of these beneficial effects is debated, with many studies invoking mechanisms of benefit beyond improvements in insulin resistance [47, 50, 52-59]. Pioglitazone improved insulinmediated vasodilation in one study where this was directly assessed. Overall, these agents induce concurrent and associated improvements in insulin resistance and vascular function. Together with the parallel results from studies using metformin, these studies support the targeting of insulin resistance as an approach to treating the endothelium in Type 2 diabetes.
Metabolic therapies: fatty acid lowering
Elevated fatty acids are a component of the insulin resistance phenotype, and likely contribute directly to tissue insulin resistance and to endothelial dysfunction. In cross-sectional studies there is an association between elevated fatty acid concentrations and vascular dysfunction [60, 61] . Experimental studies have demonstrated impairments in vascular function measurements in healthy control subjects with experimentally induced elevation in fatty acid concentrations [61] [62] [63] . Therapies that target fatty acid lowering may therefore be of benefit for vascular function. TZDs, discussed above, induce improvements in insulin resistance by manipulating cellular handling of fatty acids and may exert the beneficial effects described above via these changes. Studies separating effects on insulin sensitivity from effects on fatty acids in the beneficial effects of TZDs on the vasculature have not been performed. Similarly, insulin treatment suppresses fatty acid concentrations and this effect may contribute to the net beneficial effects of insulin treatment on the vascular endothelium. Studies separating these effects from glucose lowering and direct effects of insulin on the vascular wall have not been performed.
Other therapeutic approaches provide more focused fatty acid lowering. Acipimox, an inhibitor of lipolysis [64] , has been studied in the context of experimental elevations in non-esterified fatty acids and found to concurrently reverse fatty acid-induced insulin resistance and microvascular dysfunction [63] . In one study, gemfibrozil (a PPARalpha agonist with predominantly triglyceride-lowering action) concurrently improved vascular function and insulin sensitivity [65] . Niacin, which is used clinically for its widespread effects to lower lipid species, acts through receptordependent and receptor-independent mechanisms as a fatty acid lowering agent [66, 67] . In non-diabetic populations, niacin therapy produces improvements in endotheliumdependent vasodilation [68, 69] . However, despite fatty acid lowering effects niacin treatment improvements in insulin resistance have not been universally observed [70] [71] [72] . And no published data evaluate concurrent effects of niacin on insulin resistance and vascular function, or on insulinmediated vasodilation.
Fish oil, with omega-3 fatty acids as the main identified therapeutic constituents, present another widely used agent with lipid lowering effects including reductions in nonesterified fatty acids [73] . In the context of these complex lipid alterations, fish oil supplementation does not significantly improve insulin resistance [74, 75] but has beneficial vascular effects in populations with diabetes or obesityrelated metabolic dysfunction [76] [77] [78] . Effects on vascular insulin responses have not been evaluated to date.
In summary, the data most strongly linking improvements in vascular function with reductions in nonesterified fatty acids comes from studies with TZDs, but those data are confounded by concurrent effects on wholebody insulin sensitivity. Therapies with fatty acid-lowering effects but without confounding effects on insulin sensitivity have not been systematically evaluated for effects on vascular function, but the available data provides modest support for targeting fatty acid reductions as a component of therapies aimed at the vascular endothelium in diabetes.
Metabolic therapies: anti-inflammatories
The activation of the innate immune system in insulin resistance is another viable therapeutic target. Insulin resistant states, and hyperglycemic states in the absence of insulin resistance, are now well recognized to be associated with low-level activation of systemic inflammatory responses [79, 80] . This effect is manifest as elevations in C-reactive protein, and as increased activity of the tumor necrosis factor (TNF) system in multiple tissues [80] [81] [82] . The seminal observation in animal studies that overexpression of TNFalpha induced an insulin resistant state associated with vascular dysfunction [83, 84] prompted studies in humans that confirmed the importance of inflammation in the human condition [85, 86] . Experimental elevation of fatty acids induces a systemic inflammatory condition, and this appears to be mediated by induction of TNFalpha-mediated cellular inflammatory responses [87, 88] . Inflammatory effects of hyperglycemia have also been observed although less convincingly focused on TNFalpha responses [89, 90] .
Anti-inflammatory approaches that have been evaluated include small-molecule agents that interfere with intracellular signaling, and monoclonal antibodies that interfere with targeted extracellular components of the innate immune system. Studies evaluating effects of these therapies on insulin resistance and studies evaluating effects on vascular function have been performed, but very few studies have evaluated concurrent effects on both axes.
Monoclonal antibodies against the TNFalpha system are now widely applied in clinical rheumatology. Beneficial effects to reduce insulin resistance have been reported in populations with systemic inflammatory disease and in traditionally insulin resistant and type 2 diabetic populations [91] [92] [93] [94] [95] [96] , although others report no such benefit [93, [97] [98] [99] . Similarly, in populations with systemic inflammatory disease such therapies can improve vascular function [100] [101] [102] [103] [104] . In the few studies that have evaluated effects on vascular function in populations with insulin resistance or type 2 diabetes, improvement in vascular function has been difficult to demonstrate [91, 105] .
Recently, salsalate has been found to impair TNFalphamediated inflammation in addition to the originally recognized anti-inflammatory effects mediated by inhibition of cyclooxygenase [106] . Subsequent studies have clearly demonstrated beneficial effects on glycemia with salsalate, although surprisingly these cannot be clearly attributed to improvements in insulin resistance [107] [108] [109] . Early studies in non-diabetic populations have found that salsalate can improve vascular function [110, 111] , but studies in traditionally insulin resistant or type 2 diabetic subjects have not been published and no data are currently available to connect changes in insulin sensitivity with changes in vascular function.
Overall these data produce a perhaps surprising observation that therapeutically targeting the activated intrinsic inflammatory response in insulin resistance/Type 2 DM is beneficial for insulin resistance but not necessarily beneficial for vascular function. Further data with TNFalpha antagonists, and data with salsalate may clarify this circumstance. As with other potential therapeutic targets, studies concurrently assessing effects on both axes will be most informative.
Metabolic therapies: advanced glycosylation endproducts
The chemical reaction whereby proteins are glycosylated is spontaneous, indiscriminate and proportional to glucose concentrations. This produces a variety of circulating glycosylated proteins and their breakdown products, which are sensed at cell membranes through the receptors for advanced glycosylation products (R-AGEs) [112] . These receptors mediate cellular injury in endothelial cells, producing impaired NO production and affecting transcription of eNOS [113, 114] . Glucose reducing therapies reduce AGE generation, and as reviewed above these effects can produce improvements in vascular function. Unexpectedly, angiotensin converting enzyme inhibitors and angiotensin receptor blockers, which provide vascular benefits and are commonly used in diabetes, can also improve AGE concentrations independent of glucose lowering [115, 116] . Although blocking the receptors for AGE is conceptually obvious as a therapeutic approach, no data have been published on this topic. A number of agents are under development as direct AGE breakers, and show promising effects in animal models of diabetes [117, 118] . Human studies using direct AGE breakers in non-diabetic populations have indicated some success blocking effects of AGEs on the vasculature [119, 120] . Data evaluating these direct blockers in diabetic populations have not been published. One study in diabetic subjects has been published demonstrating a beneficial effect of benfotiamine (which can prevent AGE formation in vitro) to prevent acute impairment of endothelial function by ingested AGEs [121] . This is useful as a test of the concept, but it is not clear whether the reported benefit was via reduced production of endogenous AGEs or through effects on the concentrations of the ingested AGEs.
Vascular therapies
The dependence of insulin on the endothelium for a portion of its tissue actions, and concordance of tissue insulin resistance with vascular insulin resistance in the setting of endothelial dysfunction, prompts the hypothesis that treatments primarily targeting vascular function might improve insulin sensitivity simply by allowing improved vascular insulin response. These questions have been asked with the major clinically available therapies targeting the vasculature directly.
Vascular therapies: renin-angiotensin system antagonists
Hypertension is a common feature of obesity/insulin resistance, and is itself associated with impairments in endothelial function even in the absence of obesity. Notably, insulin resistance is prevalent even among non-obese subjects with hypertension, suggesting that impaired endothelial function is a key link between vascular and metabolic dysfunction [122, 123] . In multiple studies, treatment with antihypertensive agents in general and specifically those targeted at components of the renin-angiotensin system has been shown to improve endothelium-dependent vasodilation in hypertension (reviewed in [124] ).
As a general statement, treatment of insulin resistant subjects with ACEI or ARB improves endothelial function but produces mixed effects on whole-body insulin sensitivity. A reasonable number of studies have been performed in humans exploring whether treatment with these classes of agents can improve whole-body insulin sensitivity, unfortunately producing a mixed literature [125] [126] [127] [128] [129] . Fewer studies have directly evaluated concurrent effects on tissue and vascular insulin sensitivity [129, 130] , but this subset again produced conflicting evidence for RAS-targeted treatment to improve insulin-mediated vasodilation in humans.
These conflicting results do not appear to be attributable to agent-specific effects, or to differences by class of treatment. Even the studies that have involved randomized treatment assignments and double-blind crossover designs have produced contradictory results. No meta-analysis of these studies has been produced to date. The fact of intermittently demonstrating positive findings could indicate that treatment with a RAS-acting agent is in fact capable of improving whole-body insulin resistance, but the true effect size is moderately smaller than the demonstrable effect size in studies to date. Alternatively, it could be that there is no effect of RAS-acting agents on insulin sensitivity, and the individual studies reporting positive findings represent false positives. This possibility seems unlikely in part because positive findings have been demonstrated by multiple investigators, in well-designed studies with adequate control conditions. A third possibility is that the actions of RAS-acting agents on whole-body insulin responses is more complicated than currently appreciated, producing an effect that is incompletely measured in studies to date. Clearly further work is needed to better understand the physiology underlying these effects, and better understand the role of RASacting agents in the clinical approach to vascular and metabolic disease in diabetes and obesity. Currently available data allows us to confidently claim beneficial effects on vascular function and cardiovascular risk with RAS-acting agents, but the claim of improvement also in insulin sensitivity cannot be confidently made.
Vascular therapies: statins
The HMGcoA-reductase inhibitors, collectively called the statins, are remarkably effective cholesterol-lowering agents, and confer cardiovascular benefit in populations with CVD risk including those with obesity/insulin resistance and diabetes [131] . These agents have readily demonstrated beneficial effects on multiple aspects of vascular biology, including improvements in endothelial function and reductions in systemic inflammation [132] [133] [134] .
On this basis it is natural to hypothesize that statin treatment would be associated with an improvement in insulin sensitivity, or at least an improvement in vascular insulin sensitivity. However, studies to date evaluating this question have shown no benefit on insulin resistance despite demonstrable improvements in endothelium-dependent vasodilation [134] [135] [136] . No direct studies of effects of statins on insulin-mediated vasodilation have been published.
Recent observations of an effect of statins to increase the incidence of diabetes in large-scale clinical trials of cholesterol-lowering for CVD benefits [137] [138] [139] [140] are consistent with these observations. The assumption that therapies that improve vascular function should improve tissue metabolism is clearly not valid with statins, for unknown reasons. It could be the case that therapeutic improvement in vascular function is not sufficient to improve insulin resistance-mediated tissue vascular dysfunction. Another (non-exclusive) alternative is that there are concurrent effects of statins that aggravate metabolic status, or otherwise act in an adverse manner despite otherwise beneficial effects induced by improvements in vascular function.
Combining these observations with those from the RASacting agents provides some support for the first of these interpretations. With each of these classes, there is a clearly demonstrable improvement in endothelial function, with associated reductions in cardiovascular disease risk. But despite this improvement, benefits on tissue insulin sensitivity do not follow. This suggests that improving endothelium-dependent vasodilation per se is not sufficient to improve vascular insulin action and the component of tissue insulin sensitivity that is dependent on vascular function.
Vascular therapies: targeting NO/ET-1 balance
Vascular tone is closely regulated, and as in most biological systems this requires the actions of opposing factors. In the vasculature of skeletal muscle NO is the dominant dilator. eNOS produces NO tonically as part of a regulated balance of dilators and constrictors controlling vascular tone, and production can be acutely stimulated by agonists including insulin [16] . As noted, insulin's vasodilator action is mediated by NO, and impaired vascular insulin response is manifest as a lack of effect of insulin to produce NO, producing the resulting impairment in insulin-induced vasodilation. In the vasculature endothelin-1 (ET-1) is the dominant vasoconstrictor opposing the dilator effects of NO [141, 142] . This constrictor is also tonically produced, but in contrast to NO the production or action of ET-1 does not change significantly in response to acute stimuli. Regulators of the tonic production of ET-1 include fatty acids, glucose, and insulin but in vivo experimentation suggests that nitric oxide itself regulates ET-1 production at least as potently as these metabolic factors [85, [143] [144] [145] . Obesity/insulin resistance and diabetes are associated with increased ET-1 tone, and ET-1 is an important contributor to abnormalities in vascular tone, to impaired endothelium-dependent responses, and also to impairment in the vascular components of insulin action.
A number of NO-delivery therapies are under development [146] [147] [148] but to date these have not been tested in clinical studies addressing metabolic benefits. Other approaches to enhancing bioavailability of nitric oxide have been pursued. These include using arginase inhibitors to augment availability of the NOS substrate L-arginine [149, 150] , or using enzyme inhibitors preserving the availability of the NOS cofactor tetrahydrobiopterin, or direct supplementation with tetrahydrobiopterin [151, 152] . One study with tetrahydrobiopterin found beneficial effects on insulin resistance, although in that study there was no concurrent improvement in vascular function [153] . Asymmetric dimethylarginine (ADMA) is a regulated, endogenous inhibitor of NOS, and its levels are associated with vascular dysfunction [154] [155] [156] . No therapies have been developed as yet to manipulate ADMA concentrations (with the possible exception of ECGC from green tea, discussed below), but reductions in ADMA have been observed concurrent with improved endothelial function from statins, RAS antagonists, and other vascular therapies [157] [158] [159] [160] .
Working further downstream, the phosphodiesterase (PDE)-5 inhibitors have proven clinically useful as direct vascular-acting NO preserving therapies including in subjects with diabetes. In preclinical studies and a small number of clinical studies there appears to be the predicted benefit on endothelium-dependent vasodilation [161, 162] . One preclinical study suggests that PDE5 inhibition may provide an insulin sensitizing effect [163] but this idea has not been tested in humans to date. Given the ready clinical availability, acceptability, and low toxicity of these agents this approach warrants further exploration.
In physiologic studies ET-1 antagonism improves vasodilation in obesity or diabetes [164] [165] [166] , and antagonizing ET-1 action in the vasculature can improve insulin resistance including vascular insulin resistance [165, [167] [168] [169] . Due in part to toxicity concerns, ET-1 antagonists have been approved only for restricted clinical uses (bosentan for primary pulmonary hypertension, and atrasentan for prostate cancer metastasis prevention). Whether agents of this class are of benefit for vascular metabolic actions in clinical obesity or diabetes is unknown, although the available data suggest a clear opportunity for benefit for both vascular outcomes and metabolic balance.
Alternative medicines
Studies of nontraditional medicines including plant-derived therapies have provided surprising insights into insulin signaling in endothelial cells, and provided some evidence for concurrent benefits on tissue insulin action and whole-body insulin sensitivity. Green tea-derived catechins, in particular epigallotechin gallate (EGCG), exert beneficial effects on endothelial function in cultured cells and in animal models, via mechanisms shared with the insulin response system [170] [171] [172] . Acute physiologic effects of EGCG to improve endothelium-dependent vasodilator function have been evaluated in humans with or without CVD risk factors [173, 174] , but studies in obesity and diabetes are lacking. In animals, concurrent effects on insulin resistance and vascular function have been reported [172] . To date one study has been published evaluating these parameters in humans, and found significant effect of green tea extract on post-meal blood pressure and insulin response, with interesting differences by catechol-O-methyl transferase (COMT) genotype [175] . The fact of shared mechanisms with insulin signaling in endothelium and promising pre-clinical data in animals suggests that green tea-based therapies may be of particular benefit in insulin resistanceassociated vascular dysfunction, but this has not yet been rigorously assessed.
The weak androgen dihydroepiandrosterone (DHEA) also exerts effects on endothelial cells, again using mechanisms parallel to insulin signaling pathways [176] . In human studies DHEA supplementation in individuals who are not deficient produces improved endothelium-dependent vasodilation [177, 178] , and has also been shown to concurrently improve insulin resistance [177] . This is at odds with the observation that DHEA concentrations are spontaneously elevated in individuals with the polycystic ovarian syndrome (PCOS), which is associated with insulin resistance and vascular dysfunction [179] , but leaves open the possibility that this agent could produce beneficial effects when used as a supplement in non-PCOS populations.
Resveratrol is a plant-derived stilbene polyphenol found in red wine, with potent endothelium-independent vasodilating effects [180] . Among multiple claimed beneficial health effects are increased transcription and action of nitric oxide synthase [181] and reduced ET-1 production or action [182, 183] . Clinical studies have shown beneficial effects on vascular function [184, 185] but where systemic metabolism has been evaluated, no effects on whole-body metabolism were observed [184] .
Emerging targets
Many of the above factors have been under investigation for decades, while others have been more recently discovered. Further, the pace of progress continues to accelerate and many novel discoveries have potential impact on vascular and metabolic status in diabetes. Advances in this field can be expected from emerging work including micro RNA species [186, 187] , modulation of endoplasmic reticulum stress [188, 189] , control of autophagy [190, 191] , and new approaches to management of hormonal control of systemic metabolism such as GLP-1-receptor targeted adducts [192] , or mixed hormonal therapies [193, 194] . Bringing these discoveries into the current body of knowledge regarding integrated effects of the vascular endothelium on vascular and metabolic disease may provide needed advances in our approach to targeting the endothelium in obesity/insulin resistance and type 2 diabetes.
Summary and future directions
Insulin resistance affects the vascular endothelium, and contributes to systemic insulin resistance by directly impairing the actions of insulin to redistribute blood flow as part of its normal actions driving muscle glucose uptake. Impaired vascular function is a component of the insulin resistance syndrome, and is a feature of type 2 diabetes. On this basis, the vascular endothelium has emerged as a therapeutic target where the intent is to improve systemic metabolic state by improving vascular function.
Many pathophysiologic features of obesity, insulin resistance, and type 2 diabetes exert direct impairment in vascular function and contribute to the adverse vascular phenotype. Individually targeting key pathophysiologic features is generally successful in terms of improving vascular function, but only approaches that address insulin sensitivity or fat distribution have provided consistent data showing concurrent improvements in systemic metabolic status. Mechanistically it appears that therapies directly targeting improved NO bioavailability or direct ET-1 antagonism may produce concurrent vascular and metabolic benefits, but it is not sufficient to improve the NO/ET-1 balance by therapies acting solely on the endothelium. In particular, RAS-acting agents and statins have widely recognized beneficial effects on vascular function but have not produced the hoped-for metabolic benefits. These observations support the notion that systemic metabolic benefits can arise from therapies targeted at the endothelium, but improving vascular insulin action does not result from all treatments that improve endothelium-dependent vasodilation. A better understanding of the mechanisms of insulin's actions in the vascular wall will advance our understanding of the specificity of these responses, and allow us to better target the vasculature for metabolic benefits. 
